keyword
MENU ▼
Read by QxMD icon Read
search

Pharmacogenomics

keyword
https://www.readbyqxmd.com/read/28806023/pharmacogenomics-and-mental-illness
#1
EDITORIAL
Keith Hansen
No abstract text is available yet for this article.
July 2017: South Dakota Medicine: the Journal of the South Dakota State Medical Association
https://www.readbyqxmd.com/read/28798474/cyp2c19-2-and-cyp2c19-17-variants-and-effect-of-tamoxifen-on-breast-cancer-recurrence-analysis-of-the-international-tamoxifen-pharmacogenomics-consortium-dataset
#2
Per Damkier, Anders Kjærsgaard, Kimberly A Barker, Deidre Cronin-Fenton, Anatasha Crawford, Ylva Hellberg, Emilius A M Janssen, Carl Langefeld, Thomas P Ahern, Timothy L Lash
The role of cytochrome P450 drug metabolizing enzymes in the efficacy of tamoxifen treatment of breast cancer is subject to substantial interest and controversy. CYP2D6 have been intensively studied, but the role of CYP2C19 is less elucidated, and we studied the association of CYPC19 genotype and recurrence of breast cancer. We used outcome and genotyping data from the large publicly available International Tamoxifen Pharmacogenomics Consortium (ITPC) dataset. Cox regression was used to compute the hazard ratios (HRs) for recurrence...
August 10, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28795399/new-pharmacogenomics-research-network-an-open-community-catalyzing-research-and-translation-in-precision-medicine
#3
M V Relling, R M Krauss, D M Roden, T E Klein, D M Fowler, N Terada, L Lin, M Riel-Mehan, T P Do, M Kubo, S W Yee, G T Johnson, K M Giacomini
The goal of pharmacogenomics research is to discover genetic polymorphisms that underlie variation in drug response. Increasingly, pharmacogenomics research involves large numbers of patients and the application of new technologies and methodologies to enable discovery. The Pharmacogenomics Research Network (PGRN) has become a community-driven network of investigators spanning scientific and clinical disciplines. Here, we highlight the activities and types of resources that enable PGRN members to enhance and drive basic and translational research in pharmacogenomics...
August 10, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28792790/recent-developments-and-future-directions-for-the-use-of-pharmacogenomics-in-cardiovascular-disease-treatments
#4
Andrew Levy, Elliot Berinstein
Cardiovascular disease is still the leading cause of death worldwide. There are many environmental and genetic factors that play a role in the development of cardiovascular disease. The treatment of cardiovascular disease is beginning to move in the direction of personalized medicine by using biomarkers from patient's genome to design more effective treatment plans. Pharmacogenomics have already uncovered many links between genetic variation and response of many different drugs. Areas covered: This article will focus on the main polymorphisms that impact the risk of adverse effects and response efficacy of statins, clopidogrel, aspirin, β-blockers, warfarin dalcetrapib and vitamin E...
August 9, 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28790862/hyperbilirubinemia-in-atazanavir-treated-hiv-infected-patients-the-impact-of-the-ugt1a1-28-allele
#5
REVIEW
Periklis Panagopoulos, Efstathios Maltezos, Angelos Hatzakis, Dimitrios Paraskevis
Combination antiretroviral treatment (cART) has significantly improved the life expectancy of people living with HIV. The life-long nature of cART increases the risk of side effects, which in some cases may have been caused by specific genetic characteristics. Patients treated with atazanavir (ATV) boosted with ritonavir (rit), which is a protease inhibitor used for the treatment of HIV, present with elevated bilirubin levels, at high proportions. ATV/rit-related hyperbilirubinemia has been previously associated with genetic characteristics in uridine diphosphate glucuronosyltransferase (UGT) enzyme...
2017: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/28790500/personomics-and-precision-medicine
#6
Roy C Ziegelstein
The importance of knowing patients as individuals has been highlighted throughout the history of medicine. However, shorter visits, electronic documentation, reliance on technology, and increasing linguistic and cultural differences between patients and physicians create more challenges to effective communication than ever before. Perhaps more concerning is the greater emphasis on aspects of care considered more precisely measurable and quantifiable, the sum of which is sometimes felt to represent the patient better than knowledge of the patient himself...
2017: Transactions of the American Clinical and Climatological Association
https://www.readbyqxmd.com/read/28782463/in-this-issue-of-pharmacogenomics
#7
Sarah Jones
No abstract text is available yet for this article.
August 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28782406/severe-sunitinib-induced-myelosuppression-in-a-patient-with-a-cyp-3a4-polymorphism
#8
Nirav D Patel, Kanishka Chakrabory, Garrett Messmer, Koyamangalath Krishnan, John B Bossaer
Sunitinib, an oral vascular endothelial growth factor receptor, is a first-line option for metastatic renal cell carcinoma and widely used in clinical practice. Despite the proven benefit of sunitnib in metastatic renal cell carcinoma, patients may suffer from a variety of adverse events including hypertension, fatigue, hypothyroidism, hand-foot skin reactions, rash, depigmentation, and myelosuppression. Myelosuppression is usually mild, transient and resolves during the two weeks at the end of each cycle where no drug is taken...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28776467/pharmacogenetics-and-the-treatment-of-asthma
#9
María Isidoro-García, Almudena Sánchez-Martín, Asunción García-Sánchez, Catalina Sanz, Belén García-Berrocal, Ignacio Dávila
Heterogeneity defines both the natural history of asthma as well as patient's response to treatment. Pharmacogenomics contribute to understand the genetic basis of drug response and thus to define new therapeutic targets or molecular biomarkers to evaluate treatment effectiveness. This review is initially focused on different genes so far involved in the pharmacological response to asthma treatment. Specific considerations regarding allergic asthma, the pharmacogenetics aspects of polypharmacy and the application of pharmacogenomics in new drugs in asthma will also be addressed...
August 4, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28771511/exploring-public-genomics-data-for-population-pharmacogenomics
#10
Kleanthi Lakiotaki, Alexandros Kanterakis, Evgenia Kartsaki, Theodora Katsila, George P Patrinos, George Potamias
Racial and ethnic differences in drug responses are now well studied and documented. Pharmacogenomics research seeks to unravel the genetic underpinnings of inter-individual variability with the aim of tailored-made theranostics and therapeutics. Taking into account the differential expression of pharmacogenes coding for key metabolic enzymes and transporters that affect drug pharmacokinetics and pharmacodynamics, we advise that data interpretation and analysis need to occur in light of geographical ancestry, if implications for drug development and global health are to be considered...
2017: PloS One
https://www.readbyqxmd.com/read/28769070/il6r-haplotype-rs4845625-t-rs4537545-c-is-a-risk-factor-for-simultaneously-high-crp-ldl-and-apob-levels
#11
A A Arguinano, E Naderi, N C Ndiaye, M Stathopoulou, S Dadé, B Alizadeh, S Visvikis-Siest
Interleukin 6 receptor (IL-6R), mediating IL-6's biological functions, plays an important role in different diseases such as diabetes, obesity and cardio-vascular diseases. In this study, we investigated the effects of two single nucleotide polymorphisms (SNPs), within the IL-6R loci, previously associated with C-reactive protein (CRP) and coronary heart diseases risk, and with controversial effects on lipids traits: SNP rs4845625 and SNP rs4537545. The results showed that both investigated SNPs were antagonistically related with CRP levels; the minor rs4845625*T allele was associated with increased CRP levels (P-value=0...
August 3, 2017: Genes and Immunity
https://www.readbyqxmd.com/read/28768489/improved-anticancer-drug-response-prediction-in-cell-lines-using-matrix-factorization-with-similarity-regularization
#12
Lin Wang, Xiaozhong Li, Louxin Zhang, Qiang Gao
BACKGROUND: Human cancer cell lines are used in research to study the biology of cancer and to test cancer treatments. Recently there are already some large panels of several hundred human cancer cell lines which are characterized with genomic and pharmacological data. The ability to predict drug responses using these pharmacogenomics data can facilitate the development of precision cancer medicines. Although several methods have been developed to address the drug response prediction, there are many challenges in obtaining accurate prediction...
August 2, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28766962/clarifying-busulfan-metabolism-and-drug-interactions-to-support-new-therapeutic-drug-monitoring-strategies-a-comprehensive-review
#13
Alan L Myers, Jitesh D Kawedia, Richard E Champlin, Mark A Kramer, Yago Nieto, Romi Ghose, Borje S Andersson
Busulfan (Bu) is an alkylating agent with a limited therapeutic margin and exhibits inter-patient variability in pharmacokinetics (PK). Despite decades of use, mechanisms of Bu PK-based drug-drug interactions (DDIs), as well as the negative downstream effects of these DDIs, have not been fully characterized. Areas covered: This article provides an overview of Bu PK, with a primary focus on how known and potentially unknown drug metabolism pathways influence Bu-associated DDIs. In addition, pharmacogenomics of Bu chemotherapy and Bu-related DDIs observed in the stem cell transplant clinic (SCT) are summarized...
August 2, 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28764766/physicians-pharmacogenomics-information-needs-and-seeking-behavior-a-study-with-case-vignettes
#14
Bret S E Heale, Aly Khalifa, Bryan L Stone, Scott Nelson, Guilherme Del Fiol
BACKGROUND: Genetic testing, especially in pharmacogenomics, can have a major impact on patient care. However, most physicians do not feel that they have sufficient knowledge to apply pharmacogenomics to patient care. Online information resources can help address this gap. We investigated physicians' pharmacogenomics information needs and information-seeking behavior, in order to guide the design of pharmacogenomics information resources that effectively meet clinical information needs...
August 1, 2017: BMC Medical Informatics and Decision Making
https://www.readbyqxmd.com/read/28762371/imatinib-induced-ophthalmological-side-effects-in-gist-patients-are-associated-with-the-variations-of-egfr-slc22a1-slc22a5-and-abcb1
#15
H-B Qiu, W Zhuang, T Wu, S Xin, C-Z Lin, H-L Ruan, X Zhu, M Huang, J-L Li, X-Y Hou, Z-W Zhou, X-D Wang
Imatinib-induced ophthalmological side-effects, including conjunctiva hemorrhage and periorbital oedema, although very common and still remain relatively little understood. The present study investigated the effects of genetic polymorphisms of drug targets and membrane transporters on these side effects. We found that the minor allele of EGFR rs10258429 and SLC22A1 rs683369 were significant risk determinants of conjunctival hemorrhage with OR of 7.061 (95%CI=1.791-27.837, P=0.005 for EGFR rs10258429 CT+TT vs CC), and 4...
August 1, 2017: Pharmacogenomics Journal
https://www.readbyqxmd.com/read/28762370/impact-of-cyp2d6-polymorphisms-on-endoxifen-concentrations-and-breast-cancer-outcomes
#16
REVIEW
G S Hwang, R Bhat, R D Crutchley, M V Trivedi
We investigated the impact of germline CYP2D6 genotyping done using the non-tumor specimen on endoxifen concentrations and/or clinical outcomes in breast cancer (BC) patients treated with tamoxifen in published studies. We evaluated published data from 13 001 patients in 29 studies. Mean±s.d. endoxifen concentrations were significantly lower in poor metabolizers (PM) versus extensive metabolizers (EM) (8.8±7.2 versus 22.3±11.8 ng ml(-1); P<0.05). The PM status did not influence clinical outcomes in majority of the studies...
August 1, 2017: Pharmacogenomics Journal
https://www.readbyqxmd.com/read/28761069/evidence-for-treatment-by-biomarker-interaction-for-fda-approved-oncology-drugs-with-required-pharmacogenomic-biomarker-testing
#17
Alexandre Vivot, Isabelle Boutron, Geoffroy Béraud-Chaulet, Jean-David Zeitoun, Philippe Ravaud, Raphaël Porcher
For oncology drugs that were approved by the US Food and Drug Administration (FDA) and required pharmacogenomic biomarker testing, we describe 1) the use of enrichment (biomarker-positive patients) and a randomized controlled design by pre-approval trials and 2) the treatment-by-biomarker interaction. From the 137 drugs included in the FDA table, we selected the 22 oncology drugs with required genetic testing in their labels. These drugs corresponded to 35 approvals supported by 80 clinical studies included in the FDA medical officer reviews of efficacy...
July 31, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28759833/anti-oxidative-treatment-with-vitamin-e-improves-peripheral-vascular-function-in-patients-with-diabetes-mellitus-and-haptoglobin-2-2-genotype-a-double-blinded-cross-over-study
#18
Jonia Amer Alshiek, Lior Dayan, Rabea Asleh, Shany Blum, Andrew P Levy, Giris Jacob
Vascular dysfunction in both conduit arteries and small vessels is a major contributor to the development of cardiovascular disease (CVD) in diabetes mellitus (DM). In diabetes there is a process of systemic chronic inflammation accompanied by high oxidative stress causing a subsequent decrease in vascular reactivity and negatively affect the metabolic processes responsible for functioning of the microvasculature. Vitamin E is classified as an antioxidant due to its ability to scavenge lipid radicals and terminate oxidative chain reactions...
July 13, 2017: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/28757317/challenges-in-ordering-and-interpreting-pharmacogenomic-tests-in-clinical-practice
#19
EDITORIAL
Ann M Moyer, Carolyn R Rohrer Vitek, Jyothsna Giri, Pedro J Caraballo
No abstract text is available yet for this article.
July 27, 2017: American Journal of Medicine
https://www.readbyqxmd.com/read/28752057/possible-adverse-effects-of-immunotherapy-in-non-small-cell-lung-cancer-treatment-and-follow-up-of-three-cases
#20
Paul Zarogoulidis, Panos Chinelis, Anastasia Athanasiadou, Theodora Tsiouda, Georgia Trakada, Anastasios Kallianos, Lemonia Veletza, Dimitris Hatzibougias, Electra Mihalopoulou, Eirini Goupou, Christoforos Kosmidis, Chrysanthi Sardeli, Haidong Huang, Wolfgang Hohenforst-Schmidt
In the past decade novel agents are on the market for non-small cell lung cancer adenocarcinoma based on pharmacogenomics. The epidermal growth factor receptor mutation, anaplastic lymphoma kinase and programmed death-ligand 1 investigation is necessary in the everyday clinical practice for the oncologic patient. Immunotherapy is nowadays the novel therapy for advanced stage non-small cell lung cancer with two agents nivolumab and pembrolizumab. In the current case series we will present adverse effects from our centers and comment on the treatment and follow-up of the patients...
2017: Respiratory Medicine Case Reports
keyword
keyword
839
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"